glp/gip/glucagon & cagrilintide 8mg/2mg The viral peptide headline sounds dramatic because it blends several different stories into one. FDA approval. Visceral fat. GLP-1 style receptors. An 80% fat reduction number. But the details matter. The FDA-approved GLP-3 Cagrilintide Research Peptide |
Description
These small chains of amino acids act as signaling molecules in the body, helping to accelerate healing, reduce inflammation, and even stimulate bone growth
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently without UK marketing authorisation from the MHRA or EMA
It consists of 15 amino acids and has been studied extensively in preclinical research for its potential to support tissue repair, reduce inflammation, and protect the gastrointestinal system
No human clinical trials have been published for either compound
